Company Description
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Its lead product candidate, ciltacabtagene autoleucel, or cilta-cel, is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.
In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China.
The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, and a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3.
The company was founded in 2014 and is headquartered in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 5, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,609 |
| CEO | Ying Huang |
Contact Details
Address: 2101 Cottontail Lane Somerset, New Jersey 08873 United States | |
| Phone | 732 317 5050 |
| Website | legendbiotech.com |
Stock Details
| Ticker Symbol | LEGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 0001801198 |
| CUSIP Number | 52490G102 |
| ISIN Number | US52490G1022 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ying Huang Ph.D. | Chief Executive Officer and Director |
| Jessie Yeung M.B.A. | Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Doug Wallace | Vice President of Operations |
| Joanne Choi | Senior Manager of Investor Relations |
| James Pepin J.D. | General Counsel |
| Tim Roberts | Global Compliance Officer |
| Deborah Wong | Executive Director of Strategic Marketing and Corporate Communications |
| Elaine Qian | Vice President and Global Head of Human Resources |
| Dr. Guowei Fang Ph.D. | President of Research and Development |
| Dr. Mythili Koneru M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2025 | 144 | Filing |
| Mar 11, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 11, 2025 | 6-K | Report of foreign issuer |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Jan 22, 2025 | 6-K | Report of foreign issuer |
| Jan 14, 2025 | 6-K | Report of foreign issuer |
| Jan 10, 2025 | 144 | Filing |
| Dec 26, 2024 | 144 | Filing |
| Dec 26, 2024 | 144 | Filing |